Core Insights - OS Therapies has been invited to participate in the "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics" Spotlight Panel at BioFuture 2025, highlighting its focus on innovative cancer treatments [1][3] - The company plans to submit a Biologics Licensing Application (BLA) to the FDA in Q4 2025, aiming for approval that could lead to a Priority Review Voucher (PRV) sale to fund further clinical development [2][4] - OS Therapies' lead asset, OST-HER2, is an immunotherapy targeting HER2 protein, showing promising results in clinical trials for osteosarcoma and breast cancer [4][5] Company Overview - OS Therapies is a clinical-stage oncology company focused on developing treatments for osteosarcoma and other solid tumors, leveraging a unique listeria monocytogenes platform technology [3][4] - The company has received multiple designations from the FDA, including Rare Pediatric Disease Designation and Fast-Track status for OST-HER2, which has shown statistically significant benefits in clinical trials [4] - OS Therapies is also advancing next-generation Antibody Drug Conjugates (ADCs) and Drug Conjugates (DCs) through its proprietary technology [5][6]